Trevi Therapeutics (TRVI) Competitors $2.77 -0.23 (-7.67%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TRVI vs. VNDA, VYNE, PTI, CARA, NUVB, ETNB, TYRA, RAPP, RLAY, and ERASShould you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include Vanda Pharmaceuticals (VNDA), VYNE Therapeutics (VYNE), Proteostasis Therapeutics (PTI), Cara Therapeutics (CARA), Nuvation Bio (NUVB), 89bio (ETNB), Tyra Biosciences (TYRA), Rapport Therapeutics (RAPP), Relay Therapeutics (RLAY), and Erasca (ERAS). These companies are all part of the "medical" sector. Trevi Therapeutics vs. Vanda Pharmaceuticals VYNE Therapeutics Proteostasis Therapeutics Cara Therapeutics Nuvation Bio 89bio Tyra Biosciences Rapport Therapeutics Relay Therapeutics Erasca Vanda Pharmaceuticals (NASDAQ:VNDA) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, community ranking, profitability, media sentiment, valuation and analyst recommendations. Do analysts rate VNDA or TRVI? Vanda Pharmaceuticals currently has a consensus price target of $15.50, indicating a potential upside of 216.33%. Trevi Therapeutics has a consensus price target of $7.43, indicating a potential upside of 168.18%. Given Vanda Pharmaceuticals' higher possible upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Trevi Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vanda Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Trevi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Does the media refer more to VNDA or TRVI? In the previous week, Vanda Pharmaceuticals and Vanda Pharmaceuticals both had 3 articles in the media. Vanda Pharmaceuticals' average media sentiment score of 0.62 beat Trevi Therapeutics' score of 0.19 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in VNDA or TRVI? Vanda Pharmaceuticals received 449 more outperform votes than Trevi Therapeutics when rated by MarketBeat users. Likewise, 66.87% of users gave Vanda Pharmaceuticals an outperform vote while only 63.77% of users gave Trevi Therapeutics an outperform vote. CompanyUnderperformOutperformVanda PharmaceuticalsOutperform Votes53766.87% Underperform Votes26633.13% Trevi TherapeuticsOutperform Votes8863.77% Underperform Votes5036.23% Is VNDA or TRVI more profitable? Trevi Therapeutics has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -8.59%. Vanda Pharmaceuticals' return on equity of -3.02% beat Trevi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vanda Pharmaceuticals-8.59% -3.02% -2.52% Trevi Therapeutics N/A -63.31%-57.06% Which has preferable valuation and earnings, VNDA or TRVI? Vanda Pharmaceuticals has higher revenue and earnings than Trevi Therapeutics. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVanda Pharmaceuticals$192.64M1.48$2.51M-$0.28-17.50Trevi TherapeuticsN/AN/A-$29.07M-$0.44-6.30 Which has more risk and volatility, VNDA or TRVI? Vanda Pharmaceuticals has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Do institutionals and insiders believe in VNDA or TRVI? 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 8.9% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 24.4% of Trevi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryVanda Pharmaceuticals beats Trevi Therapeutics on 9 of the 17 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRVI vs. The Competition Export to ExcelMetricTrevi TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$230.60M$6.48B$5.07B$8.89BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-6.304.4283.5712.93Price / SalesN/A375.031,220.3088.33Price / CashN/A52.5939.4636.25Price / Book3.6010.126.936.25Net Income-$29.07M$153.61M$119.12M$225.93M7 Day Performance-3.15%-2.00%-1.83%-1.32%1 Month Performance-17.31%-7.47%-3.64%0.60%1 Year Performance114.73%31.80%31.64%26.23% Trevi Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVITrevi Therapeutics3.4138 of 5 stars$2.77-7.7%$7.43+168.2%+113.1%$230.60MN/A-6.3020VNDAVanda Pharmaceuticals4.4326 of 5 stars$4.90-0.4%$15.50+216.3%+36.9%$286.88M$192.64M0.00203VYNEVYNE Therapeutics2.55 of 5 stars$2.82+3.3%$6.88+143.8%-28.6%$40.27M$420,000.000.0030Analyst ForecastPTIProteostasis TherapeuticsN/AN/AN/AN/A$37.57M$5M-0.6244Gap UpCARACara Therapeutics3.9304 of 5 stars$0.31flat$2.32+660.7%-71.2%$16.51M$20.97M0.0055Analyst ForecastNUVBNuvation Bio2.7307 of 5 stars$2.59flat$6.60+155.3%+91.5%$871.71MN/A0.0060ETNB89bio1.4925 of 5 stars$7.98-0.1%$30.33+280.1%+3.1%$847.95MN/A0.0040TYRATyra Biosciences3.0757 of 5 stars$15.87-2.1%$31.00+95.3%+40.8%$820.27MN/A0.0020RAPPRapport Therapeutics1.8437 of 5 stars$22.19-0.4%$35.00+57.7%N/A$814.92MN/A0.00N/ANews CoverageRLAYRelay Therapeutics3.2712 of 5 stars$4.66-2.9%$21.22+355.4%-44.5%$803.44M$25.55M0.00304Gap DownHigh Trading VolumeERASErasca2.8027 of 5 stars$2.64-5.4%$6.08+130.4%+17.3%$788.81MN/A0.00126Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies VNDA Alternatives VYNE Alternatives PTI Alternatives CARA Alternatives NUVB Alternatives ETNB Alternatives TYRA Alternatives RAPP Alternatives RLAY Alternatives ERAS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TRVI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
